

0. Country information

Record ID (Country) _____

Please list the key individuals who contributed to the completion of this questionnaire: one principal contact person for the data collection and for additional persons, please provide: first name, surname, and email.

Thank you.

Principal contact person

First name: _____

Principal contact person

Surname: _____

Principal contact person

Job title: _____

Principal contact person

Organisation: _____

Principal contact person

email: _____

Principal contact person

Phone number: _____

Have other persons been involved in completion of data?

Yes

No

Please list* any additional people:

*Name, surname and email _____

1. Enabling environment

Please enter the latest available data. If new data are not available, please go to the bottom of the form and tick 'complete' and 'save'.

Enabling environment

Q1 Does your country have a national strategy, plan or policy for the prevention and control of viral hepatitis B and C virus?

- Yes (stand alone)
- Yes (integrated within a broader strategy, i.e. infectious disease)
- Under development
- No
- Do not know

Q1.1 If yes, when was the national strategy, plan or policy last updated (or published if no updates after initial publication)

(Year)

Q1.2 If yes, are there funds allocated from the national budget to implement the strategy, plan or policy?

- Yes
- No
- Don't know
- Other

Q1.2.1 Please specify:

Q1.3 If no, are there plans in place to develop a national strategy, plan or policy for viral hepatitis in the next two years?

- Yes
- No
- Don't know
- Other

Q1.3.1 Please specify:

Q1.4 If yes, does the plan include targets and indicators?

- Yes
- No
- Don't know

Q1.4.1 If yes, do these targets and indicators align with the Regional action plans for ending "AIDS and the epidemics of viral hepatitis and sexually transmitted infections 2022-2030" ?

- Yes
- No
- Don't know

Q1.5 Do you have any comments about the policy environment in your country relating to the prevention and control of viral hepatitis B and C?

2. Epidemiology

Please enter the latest available data. If new data are not available, please go to the bottom of the form and tick 'complete' and 'save'.

Epidemiology Hepatitis B virus (HBV) - Prevalence

Q2. Are data available on the estimated number of all people living with chronic hepatitis B virus (HBV) infection (prevalence) (diagnosed and undiagnosed) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q2.1 Please specify the region(s) or city(ies) from which data are available:

Q2.2 Estimated number of people living with chronic HBV infection (HBsAg positive) (diagnosed and undiagnosed), by the end of the reporting year or latest year with available data:

Q2.2.1a If available: upper bound of the confidence interval or other measure of uncertainty:

Q2.2.1b If available: lower bound of the confidence interval or other measure of uncertainty:

Q2.2.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q2.2.2.1 Please specify

Q2.2.3 Data Collection Period from:

(Year)

Q2.2.4 Data Collection Period to:

(Year)

Q2.3 Please provide any further details, including the reference for any available peer reviewed publications:

Q2.4 Are data available on the estimated number of all migrants (people born abroad) living with chronic HBV infection, diagnosed and undiagnosed, in your country?

- National-level data available
 Regional-level data available
 City-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q2.4.1 Please specify the region(s) or city(ies) from which data are available:

Q2.5 Estimated number of all migrants (people born abroad) living with chronic HBV infection (HBsAg positive), diagnosed and undiagnosed, in your country, by the end of reporting year or most recent year with available data:

Q2.5.1 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q2.5.1.1 Please specify

Q2.5.2 Data Collection Period from:

(Year)

Q2.5.3 Data Collection Period to:

(Year)

Q2.6 Please provide any further details, including the reference for any available peer reviewed publications:

Q2.7 Are data available on the estimated hepatitis D virus (HDV) (anti-HDV IgG) prevalence amongst HBsAg-positive individuals (diagnosed and undiagnosed) in your country?

- Yes
 No
 Don't know

Q2.7.1 Estimated HDV (anti-HDV IgG) prevalence amongst HBsAg-positive individuals (diagnosed and undiagnosed) in your country, by the end of reporting year or latest year with available data (%):

Q2.7.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q2.7.2.1 Please specify

Q2.7.3 Data Collection Period from:

(Year)

Q2.7.4 Data Collection Period to:

(Year)

Q2.8 Please provide any further details, including the reference for any available peer reviewed publications:

Epidemiology Hepatitis B virus (HBV) - Incidence

Q2.9 Are data available on the estimated number of new chronic HBV infections (incidence) (diagnosed and undiagnosed) during year of reporting or latest year with available data?

- National-level data available
 Regional-level data available
 City-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q2.9.1 Please specify the region(s) or city(ies) from which data are available:

Q2.10 Estimated number of new chronic HBV infections (incidence) (diagnosed and undiagnosed) during year of reporting or latest year with available data :

Q2.10.1a If available: upper bound of the confidence interval or other measure of uncertainty:

Q2.10.1b If available: lower bound of the confidence interval or other measure of uncertainty:

Q2.10.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q2.10.2.1 Please specify:

Q2.10.3 Data Collection Period from:

(Year)

Q2.10.4 Data Collection Period to:

(Year)

Q2.11 Please provide any further details, including the reference for any available peer reviewed publications:

Epidemiology Hepatitis B virus (HBV) - HBV infection among children aged five years or younger

Q2.12 Are data available from a survey or modelling on the prevalence of children aged five years or younger with evidence of HBV infection, in your country?

- National-level data available
 Regional-level data available
 City-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q2.12.0 Please specify the region(s) or city(ies) from which data are available:

Q2.12.1 Estimated proportion of surveyed children five years of age or younger with biomarkers of past or present infection and/or chronic infection (HBsAg-positive test) (%):

Q.2.12.1a If available: upper bound of the confidence interval or other measure of uncertainty:

Q.2.12.1b If available: lower bound of the confidence interval or other measure of uncertainty:

Q2.12.2 If available, what is the number of surveyed children five years or younger of age with biomarkers of past or present infection and/or chronic infection (HBsAg-positive test)

Q.2.12.3 If available, what is the number of children five years of age or younger in surveys with HBsAg result

Q2.12.4 Source of data:

- Survey
 Modelling
 Other

Q2.12.4.1 Please specify:

Q2.12.5 Data Collection Period from:

(Year)

Q2.12.6 Data Collection Period to:

(Year)

Q2.12.7 Please provide any further details, including the reference for any available peer reviewed publications:

Epidemiology Hepatitis C virus (HCV) - Prevalence

Q2.13 Are data available on the estimated number of all people living with current chronic hepatitis C virus (HCV) infection (RNA positive, diagnosed and undiagnosed) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q2.13.1 Please specify the region(s) or city(ies) from which data are available:

Q2.14 Estimated number of people living with current chronic HCV (RNA positive), (diagnosed and undiagnosed), by the end of reporting year or the latest year with available data:

Q2.14.1a If available: upper bound of the confidence interval or other measure of uncertainty:

Q2.14.1b If available: lower bound of the confidence interval or other measure of uncertainty:

Q2.14.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q2.14.2.1 Please specify

Q2.14.3 Data Collection Period from:

(Year)

Q2.14.4 Data Collection Period to:

(Year)

Q2.14.5 Please provide any further details, including the reference for any available peer reviewed publications:

Q2.15 Are data available on estimated number of people ever infected with HCV (anti-HCV positive) (diagnosed and undiagnosed), during reporting year or latest year with available data:

- National-level data available
 Regional-level data available
 City-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q2.15.1 Please specify the region(s) or city(ies) from which data are available:

Q2.16 Estimated number of people ever infected with HCV (anti-HCV positive), diagnosed and undiagnosed, by the end of reporting year or the latest year with available data:

Q2.16.1a If available: upper bound of the confidence interval or other measure of uncertainty:

Q2.16.1b If available: lower bound of the confidence interval or other measure of uncertainty (please specify):

Q2.16.2 Source of data:

- Surveillance
 - Cohort
 - Survey
 - Modelling
 - Other
-

Q2.16.2.1 Please specify

Q2.16.3 Data Collection Period from:

(Year)

Q2.16.4 Data Collection Period to:

(Year)

Q2.17 Please provide any further details, including the reference for any available peer reviewed publications:

Q2.18 Are there data on the estimated number of all migrants (people born abroad) living with current chronic HCV infection (RNA positive), diagnosed and undiagnosed, in your country?

- National-level data
- Regional-level data
- City-level data
- No data available

Please indicate the largest geographical level for which data are available.

Q2.18.1 Please specify the regions(s) or city(ies) from which data are available:

Q2.19 Estimated number of all migrants (people born abroad) living with current chronic HCV infection (RNA positive), diagnosed and undiagnosed, in your country, by the end of reporting year or most recent year with available data:

Q2.19.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q2.19.1.1 Please specify

Q2.19.2 Data Collection Period from:

(Year)

Q2.19.3 Data Collection Period to:

(Year)

Q2.20 Please provide any further details, including the reference for any available peer reviewed publications:

Q2.21 Are data available on the estimated number of migrants (people born abroad) ever diagnosed with HCV (anti-HCV positive), diagnosed and undiagnosed, in your country?

- National-level data available
 Regional-level data available
 City-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q2.21.1 Please specify the regions(s) or city(ies) from which data are available:

Q2.22 Estimated number of migrants (people born abroad) ever infected with HCV (anti-HCV positive), diagnosed and undiagnosed, in your country, by the end of reporting year or year with latest available data:

Q2.22.1 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q2.22.1.1 Please specify

Q2.22.2 Data Collection Period from:

(Year)

Q2.22.3 Data Collection Period to:

(Year)

Q2.23 Please provide any further details, including the reference for any available peer reviewed publications:

Epidemiology Hepatitis C virus (HCV) - Incidence

Q2.24 Are data available on the estimated number of new chronic HCV infections (incidence) (diagnosed and undiagnosed) during year of reporting or the latest year with available data?

- National-level data available
 Regional-level data available
 City-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q2.24.1 Please specify the region(s) or city(ies) from which data are available:

Q2.25 Estimated number of new chronic HCV infections (diagnosed and undiagnosed) during reporting year or latest year with available data (incidence):

Q2.25.1a If available: upper bound of the confidence interval or other measure of uncertainty (please specify):

Q2.25.1b If available: lower bound of the confidence interval or other measure of uncertainty (please specify):

Q2.25.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q2.25.2.1 Please specify

Q2.25.3 Data Collection Period from:

(Year)

Q2.25.4 Data Collection Period to:

(Year)

Q2.26 Please provide any further details, including the reference for any available peer reviewed publications:

Epidemiology Mortality - deaths from hepatocellular carcinoma related to hepatitis B and C

Q.2.27 Are national-level data available on the number of deaths from hepatocellular carcinoma related to hepatitis B and C during year of reporting, or year of most recent data?

- Yes
 No
 Don't know

Q.2.27.1 Number of deaths from hepatocellular carcinoma related to hepatitis B during year of reporting, or year of most recent data:

Q.2.27.2 Number of deaths from hepatocellular carcinoma related to hepatitis C during year of reporting, or year of most recent data:

Q2.27.3 Source of data:

- Cohort
 Survey
 Modelling
 Other

Q2.27.3.1 Please specify

Q2.27.4 Data Collection Period from:

(Year)

Q2.27.5 Data Collection Period to:

(Year)

Q2.28 Please provide any further details, including the reference for any available peer reviewed publications:

Epidemiology Mortality - deaths from cirrhosis related to hepatitis B and C

Q.2.29 Are national-level data available on the number of deaths from cirrhosis related to hepatitis B and C during year of reporting, or year of most recent data?

- Yes
 No
 Don't know

Q.2.29.1 Number of deaths from cirrhosis related to hepatitis B during year of reporting, or year of most recent data:

Q.2.29.2 Number of deaths from cirrhosis related to hepatitis C during year of reporting, or year of most recent data:

Q2.29.3 Source of data:

- Cohort
 Survey
 Modelling
 Other

Q2.29.3.1 Please specify

Q2.29.4 Data Collection Period from:

(Year)

Q2.29.5 Data Collection Period to:

(Year)

Q2.30 Please provide any further details, including the reference for any available peer reviewed publications:

3. Prevention

Please enter the latest available data. If new data are not available, please go to the bottom of the form and tick 'complete' and 'save'.

Prevention and vaccination Policy

Q3 In your country, is there a national policy/programme for Hepatitis B virus (HBV) vaccination for the following populations? Please check all that apply:

- Healthcare workers
- Migrants
- Men who have sex with men (MSM)
- People in prisons and other closed settings
- People living with HIV (PLHIV)
- Pregnant women
- People who inject drugs (PWID)
- All of the above
- None of the above
- Don't know
- Other:

Q3.1 Please specify:

Q3.2 What is the HBV vaccination policy for healthcare workers (HCW) in your country?

- HBV vaccination not offered to HCW
- Mandatory for all HCW
- Offered to all HCW
- Mandatory for HCW perceived to be at high risk of HBV infection
- Offered to HCW perceived to be at high risk of HBV infection
- Other

Q3.2.1 If one of these options is chosen, please provide details: (e.g. which groups of HCW qualify)

Vaccination coverage People who inject drugs (PWID)

Q3.3 Are data available on coverage of HBV vaccination for people who inject drugs (PWID)?

- National-level data available
- Regional-level data available
- City-level data available
- clinic-level data available
- No data available

Please indicate the largest geographical level for which data are available.

Q3.3.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q3.3.2 Estimated proportion of people who inject drugs fully vaccinated among those without existing immunity from prior infection (%):

Q3.3.3 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q3.3.3.1 Please specify

Q3.3.4 Data Collection Period from:

(Year)

Q3.3.5 Data Collection Period to:

(Year)

Q3.3.6 Please provide any further details, including details on source of data if applicable (ex. serology, medical records, self-report):

Vaccination Coverage Men who have sex with men (MSM)

Q3.4 Are data available on coverage of HBV vaccination for men who have sex with men (MSM)?

Please indicate the largest geographical level for which data are available.

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Q3.4.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q3.4.2 Estimated proportion of MSM fully vaccinated among those without existing immunity from prior infection (%):

Q3.4.3 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q3.4.3.1 Please specify

Q3.4.4 Data Collection Period from:

(Year)

Q3.4.5 Data Collection Period to:

(Year)

Q3.4.6 Please provide any further details, including details on source of data if applicable (ex. serology, medical records, self-report):

Vaccination coverage**Healthcare workers (HCW)**

Q3.5 Are data available on coverage of HBV vaccination for HCW?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q3.5.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q3.5.2 Please specify the groups of HCW for which there are data:

- Carers / nurse assistants
 Nurses
 Phlebotomist (people drawing blood)
 Doctors
 Surgeons
 other groups

Q3.5.2.1 Please specify:

Q3.5.3 Estimated proportion of HCW fully vaccinated (among those eligible for the vaccine according to your national policy) (%):

Q3.5.4 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q3.5.4.1 Please specify

Q3.5.5 Data Collection Period from:

(Year)

Q3.5.6 Data Collection Period to:

(Year)

Q3.5.7 Please provide any further details, including details on source of data if applicable (ex. serology, medical records, self-report):

Vaccination coverage People in prisons

Q3.6 Are data available on coverage of HBV vaccination for people in prison?

- National-level data available
 Regional-level data available
 Prison-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q3.6.1 Please specify the regions(s) or prison(s) from which data are available:

Q3.6.2 Estimated proportion of people in prison fully vaccinated (among those eligible for the vaccine) (%):

Q3.6.3 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q3.6.3.1 Please specify

Q3.6.4 Data Collection Period from:

(Year)

Q3.6.5 Data Collection Period to:

(Year)

Q3.7 Please provide any further details, including details on source of data if applicable (e.g. data related to procurement):

Prevention Injection safety

Q3.8 Are data available on the coverage of safety engineered sharps* in healthcare settings?

- National-level data available
 Regional-level data available
 Hospital-level data available
 No data available

Please indicate the largest geographical level for which data are available.

*a non- needle sharp or needle device with a built-in safety feature or mechanisms that effectively reduces the risk of an exposure incident.

Q3.8.1 Please specify the regions(s) or hospital(s) from which data are available:

Q3.8.2 Estimated proportion of sharps purchased for use in healthcare settings that are safety engineered sharps (%):

Q3.8.3 Source of data:

- Survey
- Modelling
- Other

Q3.8.3.1 Please specify

Q3.8.4 Data Collection Period from:

(Year)

Q3.8.5 Data Collection Period to:

(Year)

4. Mother-to-child transmission

Please enter the latest available data. If new data are not available, please go to the bottom of the form and tick 'complete' and 'save'.

Mother-to-child transmission HBV screening of pregnant women

Q4 In your country, is there universal screening of pregnant women for HBV infection (HBsAg)?

Yes
 No
 Don't know

Q4.1 If yes, is there a national coordinator for the antenatal care programme for HBV?

Yes
 No

Q4.1.1 Please provide details of where the coordinator is based:

Ministry of Health
 Public Health office
 Child Health Programme
 Virology
 Obstetric
 Primary care sector
 Other
 Don't know

Q4.1.1.1 Please specify

Q4.1.2 Does this national coordinator collect data to monitor the antenatal care programme for HBV?

Yes
 No
 Don't know

Q4.1.3 Is this data available online?

Yes
 No
 Don't know

Q4.1.4 please provide details:

Q4.2 Are data available on coverage of HBV screening for pregnant women?

National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q4.2.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q4.3 Estimated proportion of pregnant women screened for HBsAg during year of reporting or year of most recent data available (%):

Q4.3.1 Estimated proportion of pregnant women screened for HBsAg, who tested positive during year of reporting or year of most recent data (%):

Q4.3.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q4.3.2.1 Please specify

Q4.3.3 Data Collection Period from:

(Year)

Q4.3.4 Data Collection Period to:

(Year)

Q4.4 Please provide any further details, if available:

Mother-to-child transmission Treatment of HBV in pregnant women

Q4.5 Do national guidelines include provision of antiviral treatment to pregnant women testing positive for HBV as a measure to prevent mother to child transmission of HBV?

- Yes
 No
 Don't know

Q4.6 If pregnant women testing positive for HBV receive antiviral treatment, what are the indications that qualify them for treatment?

- Being HBsAg positive
 Being HBsAg and HBeAg
 Having a high HBV DNA (e.g. >200,000 IU/mL)
 Other
 Don't know

Q4.6.1 Please specify

Q4.7 Are there data on the numbers of pregnant women testing positive for HBV and receiving antiviral treatment?

- Yes
 No

Q4.7.1 HBV positive pregnant women eligible for antiviral treatment, who received treatment during year of reporting or year of most recent data?

Number of HBV positive pregnant women, who received treatment, during year of reporting or year of most recent data? Number of HBV positive pregnant women, eligible for antiviral treatment, during year of reporting or year of most recent data?

% of HBV positive pregnant women, eligible for antiviral treatment who received treatment:

Please click once in this field to view percentage.

Q4.7.2 If data on the numerator or/and denominator are not available, please enter estimated proportion of HBV positive pregnant women, eligible for antiviral treatment, who received treatment during year of reporting or year of most recent data - if available

Q4.7.3 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q4.7.3.1 Please specify

Q4.7.4 Data Collection Period from:

(Year)

Q4.7.5 Data Collection Period to:

(Year)

Mother-to-child transmission Treatment of infants born to mothers diagnosed with HBV

Q4.8 What post-exposure prophylaxis measures for infants born to mothers diagnosed with HBV are included in the national protocol/programme?

- Birth dose hepatitis B vaccine followed by 2-3 vaccine doses as per the schedule
 Hepatitis B immunoglobulin (HBIG)
 Other
 Don't know

Please tick all that apply

Q4.8.1 Please specify

Q4.9 Are data available on coverage of HBV vaccine birth dose among infants, born to mothers diagnosed with HBV?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q4.9.1 specify the region(s), city(ies), or clinic(s) from which data are available:

Q4.10 Estimated proportion of infants born to mothers diagnosed with HBV, receiving HBV birth dose vaccine during year of reporting or year of most recent data (%)?

Q4.10.1 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q4.10.1.1 Please specify

Q4.10.2 Data Collection Period from:

(Year)

Q4.10.3 Data Collection Period to:

(Year)

Q4.10.4 Please provide any further details, including details on source of data if applicable (ex. serology, medical records, self-report):

Q4.11 Estimated proportion of infants born to mothers diagnosed with HBV, receiving TIMELY HBV birth dose vaccine (i.e. within 24 hours of birth) during year of reporting or year of most recent data (%):

Q4.11.1 Source of data:

- Surveillance
 - Cohort
 - Survey
 - Modelling
 - Other
-

Q4.11.1.1 Please specify

Q4.11.2 Data Collection Period from:

(Year)

Q4.11.3 Data Collection Period to:

(Year)

Q4.12 Please provide any further details, including details on source of data if applicable (ex. serology, medical records, self-report):

Q4.13 Estimated proportion of eligible infants born to mothers diagnosed with HBV, receiving HBIG during year of reporting or year of most recent data (%):

Q4.13.1 Source of data:

- Surveillance
 - Cohort
 - Survey
 - Modelling
 - Other
-

Q4.13.1.1 Please specify

Q4.13.2 Data Collection Period from:

(Year)

Q4.13.3 Data Collection Period to:

(Year)

Q4.14 Please provide any further details, including details on source of data if applicable (ex. serology, medical records, self-report):

Q4.15 Estimated proportion of eligible infants born to mothers diagnosed with HBV, receiving TIMELY hepatitis B immune globulin (HBIG) (i.e. within 24 hours of birth) during year of reporting or year of most recent data (%):

Q4.15.1 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q4.15.1.1 Please specify

Q4.15.2 Data Collection Period from:

(Year)

Q4.15.3 Data Collection Period to:

(Year)

Q4.16 Please provide any further details, including details on source of data if applicable (ex. serology, medical records, self-report):

Q4.17 Are data available on the rate of mother to child transmission of HBV (i.e the proportion of HBsAg-positive infants (numerator) among those infants born to HBsAg positive mothers (denominator)?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q4.17.1 Please specify the region(s), city(ies), or clinic(s) from which data are available:

Q4.18 Proportion of HBsAg-positive infants (numerator) among those infants born to HBsAg positive mothers (denominator) during year of reporting or year of most recent data:

Number of infants testing HBsAg-positive: _____ Number of infants born to HBsAg positive mothers: _____

Proportion of infants born to HBsAg positive mothers, who tested HBsAg positive (%):

Q4.18.1 If data on the numerator or/and denominator are not available, please enter estimated proportion of infants testing HBsAg-positive among infants born to HBsAg positive mothers during year of reporting or year of most recent data (%):

Q4.18.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q4.18.2.1 Please specify

Q4.18.3 Data Collection Period from:

(Year)

Q4.18.4 Data Collection Period to:

(Year)

Q4.19 Please provide any further details, including details on source of data if applicable (ex. serology, medical records, self-report):

Mother-to-child transmission

HCV screening of pregnant women

Q4.20 In your country, is there universal screening of pregnant women for HCV infection (anti-HCV)?

- Yes
 No
 Don't know

Q4.20.1 If no, is there targeted screening of women of high risk? eg. history of drug-use etc.

- Yes
 No
 Don't know

Q4.21 Are data available on coverage of HCV screening of pregnant women?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q4.21.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q4.22 Estimated proportion of pregnant women screened for HCV during year of reporting or year of most recent data (%):

Q4.22.1 Estimated proportion of pregnant women screened for HCV who tested anti-HCV positive during year of reporting or year of most recent data (%):

Q4.22.2 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q4.22.2.1 Please specify

Q4.22.3 Data Collection Period from:

(Year)

Q4.22.4 Data Collection Period to:

(Year)

Q4.23 Please provide any further details, including details on source of data if applicable (ex. serology, medical records, self-report):

5. Testing

Please enter the latest available data. If new data are not available, please go to the bottom of the form and tick 'complete' and 'save'.

HBV testing Testing policy and guidelines

Q5 Is there a national testing policy/ strategy/ guidance from your government on HBV testing?

- Yes (stand alone)
 Yes (part of overall national plan/policy)
 Under development
 No, but international recommendations are followed (please specify*)
 No
 Do not know

Q5.1 If yes, please indicate the year of publication of the strategy /guidance currently in place in your country

_____ (Year)

Q5.2 If international guidelines are followed in your country, please indicate which?

5.3 If yes, do the testing policy/ strategy/ guidance have content on specific population groups?

- Healthcare workers
 All migrants
 Migrants from high endemicity countries
 Men who have sex with men
 People in prison
 People living with HIV
 pregnant women
 People who inject drugs
 None of the above
 Don't know
 Other

Q5.3.1 Please specify

Q5.4 If HBV testing is available for people in prison in your country, how is the testing provided?

- Offered to all people in prison
 Offered to individuals assessed to be at risk of HBV
 Opt in
 Other
 Don't know

Q5.4.1 Please specify:

Q5.5 If no, are there plans to introduce a National HBV testing policy/ strategy/ guidance or other recommendations from your government on HBV testing in the next two years?

Q5.6 Do the HBV testing policy/ strategy/ guidance make recommendations on how often certain groups should be tested for HBV?

- Yes
 no
 don't know

	Not mentioned	At least once in a lifetime	At least once a year	every 6 months	every 3 months
Healthcare workers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
All migrants	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Migrants from high endemicity countries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Men who have sex with men	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
People in prison	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
People living with HIV	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pregnant women	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
People who use drugs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q5.6.11 If other priority groups than those listed above are mentioned, please specify:

Q5.7 Which of the following HBV testing approaches are included in your national testing guidelines?

- Routine testing in areas of high prevalence
 Antenatal testing
 Provider initiated HBV testing in primary health care
 Provider initiated HBV testing in hospital settings
 STI clinics
 Self-testing
 Home testing
 Community-based HBV testing
 Testing in other health settings (e.g. Pharmacies)
 Partner notification
 None of above
 Don't know

Q5.7.1 Which of the the above approaches are implemented?

- Routine testing in areas of high prevalence
 Antenatal testing
 Provider initiated HBV testing in primary health care
 Provider initiated HBV testing in hospital settings
 STI clinics
 Self-testing
 Home testing
 Community-based HBV testing
 Testing in other health settings (e.g. Pharmacies)
 Partner notification
 None of above
 Don't know

Q5.7.2 In your country, are peer-to-peer testing services for HBV/HCV implemented in harm reduction and/or community settings?

- Yes
 No
 Don't know

Q5.8 Has your country implemented a birth cohort screening approach for HBV?

- Yes
 No
 Don't know

Q5.8.1 If yes, what is the age cohort (age group) offered HBV screening?

(example: From 30 to 60 years of age)

Q5.8.2 If yes, is birth cohort screening for HBV still ongoing?

- Yes
 No
 Don't know

Q5.8.3 If HBV screening has ended, please enter the screening period (in years):

(Example: 2020 - 2024)

Q5.8.4 If you have any other relevant information on birth cohort screening for HBV in your country, please specify:

HBV testing Access and availability

Q5.9 Are rapid Point of Care (POC) screening tests for HBV (HBsAg) available in your country?

- Yes
 No
 Don't know

Q5.10 Are there any restrictions regarding who can legally carry out a serological HBV test (i.e. HBsAg - either rapid or standard) including providing information about the result?

- Yes
 No
 Don't know

Q5.10.1 Please specify who can perform a serological HBV test (please tick all that apply)

- Specialist clinic doctor
 Any doctor
 Specialist clinic nurse
 Any nurse
 Community/NGO worker (with supervision)
 Community/NGO worker (without supervision)
 Other, please specify

Q5.10.2 Please specify:

Q5.11 Are there any restrictions regarding who can legally carry out a PCR test for HBV - including information about the result?

- Yes
 No
 Don't know

Q5.11.1 Please specify who can perform a HBV PCR test (please tick all that apply)

- Specialist clinic doctor
 Any doctor
 Specialist clinic nurse
 Any nurse
 Community/NGO worker (with supervision)
 Community/NGO worker (without supervision)
 Other, please specify
 don't know

Q5.11.1 Please specify:

Q5.12 In your country, how are the costs of HBV testing covered for the individual? Please check all that apply:

- Free for all individuals
 Free, if the individual has insurance
 Free for some population groups or if certain criteria are met - in certain settings, if a person has symptoms, for certain age groups etc. Please specify
 Available at a cost, please specify
 Other, please specify
 Don't know

Q5.12.1 Please specify groups and/or criteria:

Q5.12.2 Please provide information on the current cost to the individual for an HBV test:

Q5.12.3 Please specify other:

Q5.14 Are all people who are diagnosed with HBV reflex* tested for hepatitis D virus (HDV)?

- Yes
 No
 Don't know

*Automatic testing for hepatitis D in laboratory for all hepatitis B surface antigen (HBsAg) positive individuals

Q5.14.1 If reflex testing for HDV is not conducted, please describe which groups, if any, are tested for HDV?

HBV testing Coverage

Q5.15 Are data available on number of individuals tested for HBV (HBsAg) in your country annually?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q5.15.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q5.16 Number of individuals tested for HBV (HBsAg) during reporting year or most recent year, including rapid tests if possible:

Q5.16.1 Number of individuals tested HBsAg positive during reporting year or most recent year, including rapid tests if possible:

Q5.16.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q5.16.2.1 Please specify

Q5.16.3 Data Collection Period from:

(Year)

Q5.16.4 Data Collection Period to:

(Year)

Q5.17 Please provide any further details, including the reference for any available peer reviewed publications:

HBV testing Testing of migrants (People born abroad)

Q5.18 Are data available on the number of migrants (people born abroad) tested for HBV (HBsAg) in your country during reporting year or year with latest available data?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q5.18.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q5.19 Number of migrants (people born abroad) tested for HBV (HBsAg) during reporting year or most recent year, including rapid tests if possible:

Q5.19.1 Number of migrants (people born abroad) tested HBsAg positive during reporting year or most recent year, including rapid tests if possible:

Q5.19.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q5.19.2.1 Please specify:

Q5.19.3 Data Collection Period from:

(Year)

Q5.19.4 Data Collection Period to:

(Year)

Q5.20 Please provide any further details, including the reference for any available peer reviewed publications:

HCV testing Testing policy and guidelines

Q5.21 Is there a national strategy/guidance or other recommendations from your government on HCV testing?

- Yes (standalone)
 Yes (part of overall national strategy, guidance, or policy i.e. infectious disease)
 Under development
 No but international recommendations are followed (please specify*)
 No
 Do not know

Q5.21.1 If yes, please indicate the year of publication of the strategy /guidance currently in place in your country:

(Year)

Q5.21.2 If international guidelines are followed in your country, please specify which?

Q5.21.3 If yes, do the guidelines have content on specific key populations?

Please tick all that apply.

- Healthcare workers
 All migrants
 Migrants from high endemicity countries
 Men who have sex with men
 People in prison
 People living with HIV
 pregnant women
 People who use drugs
 None of the above
 Don't know
 Other

Q5.23.3.1 Please specify

Q5.21.4 If HCV testing is available for people in prison in your country, how is the testing provided?

- Offered to all people in prison
 Offered to individuals assessed to be at risk of HBV
 Opt in
 Other
 Don't know

Q5.21.5 Please specify:

Q5.21.6 If no, are there plans to introduce a national policy, strategy, guidance or other recommendations from your government on HCV testing in the next two years?

Q5.22 Do your HCV guidelines include recommendation for re-testing among individuals who have achieved SVR (sustained virologic response) following treatment, but who remains at risk?

- Yes
 No
 Don't know

	Not mentioned	At least once in a lifetime	At least once a year	every 6 months	every 3 months
Healthcare workers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
All migrants	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Migrants from high endemicity countries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Men who have sex with men	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
People in prison	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
People living with HIV	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pregnant women	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
People who use drugs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q5.22.9 Please specify any further details on recommendations for re-testing among individuals who have achieved SVR following treatment, if available?

Q5.23 Which of the following HCV testing approaches are included in national testing guidelines?

- Routine testing in areas of high prevalence
- Antenatal testing
- Birth cohort testing for HCV
- Provider initiated HCV testing in primary health care
- Provider initiated HCV testing in hospital settings
- STI clinics
- Self-testing
- Home testing
- Community-based HCV testing
- Testing in other health settings (e.g. Pharmacies)
- Partner notification
- None of above
- don't know

Q5.23.1 If antenatal testing for HCV is available in your country, who gets the testing?

- Every pregnant woman once
- Every pregnant woman at every pregnancy
- Only pregnant PWID
- Only pregnant women with high-risk of infection

Q5.23.2 If community-based HCV testing is included, please tick all that apply

- Harm-reduction services
- Non-government organizations (NGO's)
- Mobile clinics
- Other, please specify

Q5.23.3 Please specify:

Q5.24 Which of the following HCV testing approaches are implemented?

- Routine testing in areas of high prevalence
- Antenatal testing
- Birth cohort testing for HCV
- Provider initiated HCV testing in primary health care
- Provider initiated HCV testing in hospital settings
- STI clinics
- Self-testing
- Home testing
- Community-based HCV testing
- Testing in other health settings (e.g. Pharmacies)
- Partner notification
- None of above
- Don't know

Q5.24.1 If community-based HCV testing is implemented, please tick all that apply

- Check-points (integrated testing)
- Addiction treatment centres
- Harm-reduction settings
- Other, please specify

Q5.24.2 Please specify:

Q5.25 Has your country implemented a birth cohort screening approach for HCV?

- Yes
- No
- Don't know

Q5.25.1 If yes, what is the age cohort (age group) offered HCV screening?

_____ (example: From 30 to 60 years of age)

Q5.25.2 If yes, is HCV screening still ongoing?

- Yes
- No
- Don't know

Q5.25.3 If birth cohort screening for HCV has ended, please enter the screening period (in years):

_____ (Example: 2020 - 2024)

Q5.25.4 If you have any other relevant information on birth cohort screening for HCV in your country, please specify

HCV testing - anti-HCV Access & Availability

Q5.26 Are rapid diagnostic tests (RDTs) for HCV (anti-HCV) available in your country?

- Yes
- No
- Don't know

Q5.27 Are there any restriction regarding who can legally carry out a HCV screening test (including information about the result) for HCV (i.e. anti-HCV - either rapid or standard)?

- Yes
- No
- Don't know

Q5.27.1 If yes, please tick all, who can legally carry out a HCV screening test:

- Specialist clinic doctor
 - Any doctor
 - Specialist clinic nurse
 - Any nurse
 - Community/NGO worker (with supervision)
 - Community/NGO worker (without supervision)
 - Other, please specify
 - Don't know
-

Q5.27.2 Please specify:

Q5,28 Are there any restriction regarding who can legally carry out an HCV confirmatory test (HCV RNA) (including information about the result) for HCV?

- Yes
 - No
 - Don't know
-

Q5,28.1 Please specify who can legally perform an HCV confirmatory test (please tick all that apply)

- Specialist clinic doctor
 - Any doctor
 - Specialist clinic nurse
 - Any nurse
 - Community/NGO worker (with supervision)
 - Community/NGO worker (without supervision)
 - Other, please specify
 - Don't know
-

Q5.28.2 Please specify:

Q5.29 In your country, how are the costs of HCV testing covered for the individual? Check all that apply:

- Free for all individuals
 - Free, if the individual has insurance
 - Free for some population groups or if certain criteria are met - in certain settings, if a person has symptoms, for certain age groups etc. Please specify
 - Available at a cost
 - Other, please specify
 - Don't know
-

Q5.29.1 Please specify groups and/or criteria:

Q5.29.3 Please specify other:

Q5.30 If available at a cost, please provide information on the current cost to the individual for an HCV test?

HCV testing - anti-HCV Coverage (anti-HCV)

Q5.31 Are data available on number of individuals tested with serology for HCV (anti-HCV) in your country annually?

Please provide data from the largest geographical level for which data are available.

- National-level data available
- Regional-level data available
- City-level data available
- Clinic-level data available
- No data available

Q5.31.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q5.32 Number of individuals tested for HCV (anti-HCV) during the reporting year or latest year with data available:

Q5.32.1 Number of individuals who tested positive with serology for HCV (anti-HCV) during the reporting year or latest year with data available

Q5.32.2 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q5.32.2.1 Please specify

Q5.32.3 Data Collection Period from:

(Year)

Q5.32.4 Data Collection Period to:

(Year)

Q5.33 Please provide any further details, including the reference for any available peer reviewed publications:

HCV testing - anti-HCV People who use drugs

Q5.34 Are data available on number of people who use drugs tested for HCV (anti-HCV) in your country annually?

Please provide data from the largest geographical level for which data are available.

- National-level data available
- Regional-level data available
- City-level data available
- Clinic-level data available
- No data available

Q5.34.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q5.35 Number of people who use drugs tested for HCV (anti-HCV) during the reporting year or latest year with data available: _____

Q5.35.1 Number of people who use drugs who tested positive for HCV (anti-HCV) during the reporting year or latest year with data available _____

Q5.35.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q5.35.2.1 Please specify _____

Q5.35.3 Data Collection Period from: _____

(Year)

Q5.35.4 Data Collection Period to: _____

(Year)

Q5.36 Please provide any further details, including the reference for any available peer reviewed publications: _____

HCV testing - anti-HCV Migrants (People born abroad)

Q5.37 Are data available on number of migrants tested for HCV (anti-HCV) in your country annually?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please provide data from the largest geographical level for which data are available.

Q5.37.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available: _____

Q5.38 Number of migrants tested for HCV (anti-HCV) during the reporting year or latest year with data available: _____

Q5.38.1 Number of migrants who tested positive for HCV (anti-HCV) during the reporting year or latest year with data available _____

Q5.38.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q5.38.2.1 Please specify:

Q5.38.3 Data Collection Period from:

(Year)

Q5.38.4 Data Collection Period to:

(Year)

Q5.39 Please provide any further details, including the reference for any available peer reviewed publications:

HCV testing - anti-HCV People in prisons

Q5.40 Are data available on number of people in prisons who tested positive for HCV (anti-HCV) in your country annually?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please provide data from the largest geographical level for which data are available.

Q5.40.1 Number of people in prisons tested for HCV (anti-HCV) during the reporting year or most recent year with data available:

Q5.40.2 Number of people in prisons who tested positive for HCV (anti-HCV) during the reporting year or latest year with data available

Q5.40.3 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q5.40.3.1 Please specify:

Q5.40.4 Data Collection Period from:

(Year)

Q5.40.5 Data Collection Period to:

(Year)

Q5.41 Please provide any further details, including the reference for any available peer reviewed publications:

HCV testing HCV RNA and/or HCV core antigen

Q5.42 Are data available on number of all individuals tested for hepatitis C virus (HCV RNA and/or HCV core antigen test) annually in your country?

Please provide data from the largest geographical level for which data are available.

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Q5.42.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q5.43 Number of all individuals tested for hepatitis C virus (HCV RNA or HCV core antigen) during reporting year or most recent year of data available:

Q5.43.1 Number of all individuals tested positive for hepatitis C virus (HCV RNA or HCV core antigen) during reporting year or most recent year of data available:

Q5.43.2 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q5.43.2.1 Please specify:

Q5.43.3 Data Collection Period from

(Year)

Q5.43.4 Data Collection Period to:

(Year)

Q5.44 Please provide any further details, including the reference for any available peer reviewed publications:

HCV testing - HCV RNA and/or HCV core antigen People who use drugs

Q5.45 Are data available on number of people who use drugs, tested for hepatitis C virus (HCV RNA and/or HCV core antigen test) annually in your country?

Please provide data from the largest geographical level for which data are available.

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Q5.45.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q5.46 Number of people who use drugs, tested for hepatitis C virus (HCV RNA or HCV core antigen) during reporting year or most recent year of data available:

Q5.46.1 Number of people who use drugs, tested positive for hepatitis C virus (HCV RNA or HCV core antigen) during reporting year or most recent year of data available:

Q5.46.2 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q5.46.2.1 Please specify:

Q5.46.3 Data Collection Period from:

(Year)

Q5.46.4 Data Collection Period to:

(Year)

Q5.47 Please provide any further details, including the reference for any available peer reviewed publications:

HCV testing - HCV RNA and/or HCV core antigen People in prisons

Q5.48 Are data available on number of people in prisons, tested for hepatitis C virus (HCV RNA and/or HCV core antigen test) annually in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please provide data from the largest geographical level for which data are available.

Q5.48.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q5.49 Number of people in prisons, tested for hepatitis C virus (HCV RNA or HCV core antigen) during reporting year or most recent year of data available:

Q5.49.1 Number of people in prisons, tested positive for hepatitis C virus (HCV RNA or HCV core antigen) during reporting year or most recent year of data available:

Q5.49.2 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q5.49.2.1 Please specify:

Q5.49.3 Data Collection Period from:

(Year)

Q5.49.4 Data Collection Period to:

(Year)

Q5.50 Please provide any further details, including the reference for any available peer reviewed publications:

HCV testing - HCV RNA and/or HCV core antigen Migrants (People born abroad)

Q5.51 Are data available on number of migrants, tested for hepatitis C virus (HCV RNA and/or HCV core antigen test) annually in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please provide data from the largest geographical level for which data are available.

Q5.51.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q5.52 Number of migrants, tested for hepatitis C virus (HCV RNA or HCV core antigen) during reporting year or most recent year of data available:

Q5.52.1 Number of migrants, tested positive for hepatitis C virus (HCV RNA or HCV core antigen) during reporting year or most recent year of data available:

Q5.52.2 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q5.52.2.1 Please specify

Q5.52.3 Data Collection Period from:

(Year)

Q5.52.4 Data Collection Period to:

(Year)

Q5.53 Please provide any further details, including the reference for any available peer reviewed publications:

6. Treatment

Please enter the latest available data. If new data are not available, please go to the bottom of the form and tick 'complete' and 'save'.

HBV Treatment

Treatment guidelines

Q6 Does your country have national treatment guidelines or recommendations available for HBV?

- Yes (stand alone)
 Yes (part of overall national plan/policy)
 No, but international recommendations are followed (please specify*)
 No
 Do not know

Q6.1 If yes, please indicate the year of publication of the guidance or recommendations currently in place in your country:

_____ (Year)

Q6.2 If international guidelines for treatment of HBV are followed in your country, please indicate which?

- EASL Guidelines
 WHO Guidelines
 Other

Q6.2.1 Please specify:

Q6.3 Year of publication, if available

_____ (Year)

HBV Treatment Access & availability

Q6.4 In your country, are there any restrictions on access to HBV treatment for any groups? Please check all that apply.

- No restrictions/limitations
 People currently injecting drugs
 People formerly injecting drugs
 All migrants
 Undocumented migrants
 People in prisons
 Don't know
 Other:

Q6.4.1 Please specify:

Q6.5 In your country, how are the costs of HBV treatment covered? Check all that apply:

- Free for all individuals
 Free, if the individual has insurance
 Free for some population groups or if certain criteria are met - in certain settings, if a person has symptoms, for certain age groups etc. Please specify
 Available at a cost, please specify
 Other, please specify
 Don't know

Q6.5.1 Please specify population groups and criteria:

Q6.5.2 Please specify other:

Q6.5.2 Please provide information on the current cost for a month supply of HBV treatment:

HCV Treatment Treatment guidelines

Q6.7 Does your country have national treatment guidelines or recommendations available for HCV?

- Yes (stand alone)
 Yes (part of overall national plan/policy)
 No, but international recommendations are followed (please specify)
 No
 Do not know

Q6.7.1 If yes, please indicate the year of publication of the guidance or recommendations currently in place in your country:

(Year)

Q6.7.2 If international guidelines for treatment of HCV are followed in your country, please indicate which?

- EASL Guidelines
 WHO Guidelines
 Other

Q6.7.2.1 Please specify:

Q6.7.3 Year of publication, if available

(Year)

Q6.8 Does the HCV treatment guidelines followed in your country include recommendations on follow-up after Sustained Virological Response (SVR), please check all that apply :

- Monitoring of life-long follow-up
 Re-infections
 Re-treatment
 No recommendations for the above
 Other

Q6.8.1 Please specify:

HCV Treatment Access & availability

Q6.9 In your country, are there any restrictions on access to HCV treatment for any groups? Please check all that apply.

- No restrictions/limitations on treatment for HCV
- restrictions exist for certain groups (please tick all that apply):
 - People currently injecting drugs
 - All migrants
 - Undocumented migrants
 - People in prisons
 - Don't know
 - Other

Q6.9.1 Please specify:

Q6.10 Which of the following HCV treatment approaches are included in national treatment guidelines?

- Provider initiated HCV treatment in primary health care
- Provider initiated HCV treatment in hospital settings
- STI clinics
- Drug treatment centres
- Community-based HCV treatment
- Treatment in other health settings (e.g. mobile clinics or outreach)
- None of above
- Other

Q6.10.1 Please specify:

Q6.11 In which of the following settings is HCV treatment implemented?

- Primary health care
- Hospital settings
- STI clinics
- Drug treatment centres
- Community-based HCV treatment
- Treatment in other health settings (e.g. mobile clinics or outreach)
- None of above
- Other

Q6.11.1 Please specify:

Q6.12 In your country, how are the costs of HCV treatment covered? Check all that apply:

- Free for all individuals
- Free, if the individual has insurance
- Free for some population groups or if certain criteria are met - in certain settings, if a person has symptoms, for certain age groups etc. Please specify
- Available at a cost, please specify
- Other, please specify
- Don't know

Q6.12.1 Please specify population groups and criteria:

Q6.12.2 Please provide information of the current cost to the individual for a month supply of HCV treatment:

Q6.12.2 Please specify other:

7. Continuum of care - general

Please enter the latest available data. If new data are not available, please go to the bottom of the form and tick 'complete' and 'save'.

HBV Continuum of care - General population

Diagnosis

Q7.0 Are data available on the estimated number of people living with chronic HBV infection who have been diagnosed (HBsAg positive) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available

Q7.0.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q7.1 Total number of all people ever diagnosed and living with chronic HBV infection (HBsAg positive) up to the end of reporting year :

Q7.1.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q7.1.1.1 Please specify:

Q7.1.2 Data Collection Period from:

(Year)

Q7.1.3 Data Collection Period to:

(Year)

Q7.2 Number of people diagnosed with chronic HBV infection (HBsAg) during year of reporting or year of most recent data:

Q7.2.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q7.2.1.1 Please specify

Q7.2.2 Data Collection Period from:

(Year)

Q7.2.3 Data Collection Period to:

(Year)

Q7.2.4 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.3 Are data available on proportion of cases of HBV that have decompensated cirrhosis and/or hepatocellular carcinoma upon presentation to care (within 6 months of HBV diagnosis) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available

Q7.3.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q7.4 Percentage of individuals with chronic HBV who have decompensated cirrhosis and/or hepatocellular carcinoma upon presentation to care (within 6 months of HBV diagnosis) (%):

Q7.4.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q7.4.1.1 Please specify:

Q7.4.2 Data Collection Period from:

(Year)

Q7.4.3 Data Collection Period to:

(Year)

Q7.5 Please provide any further details, including the reference for any available peer reviewed publications:

HBV Continuum of care - General population Linkage to care

Q7.6 Is there an estimate for the total number of people who need to receive antiviral treatment for chronic HBV (diagnosed and undiagnosed) according to national or international clinical management policy or guidelines* in your country?

- National-level estimate
 Regional-level estimate
 City-level data estimate
 Clinic-level data estimate
 No estimates available

Please indicate the largest geographical level for which data are available

Q7.6.1 Please specify the regions(s), city(ies), or clinic(s) from which an estimate is available:

Q7.7 Most recent estimate of the total number of people in need of antiviral treatment for chronic HBV (diagnosed and undiagnosed):

Q7.7.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q7.7.1.1 Please specify

Q7.7.2 Data Collection Period from:

(Year)

Q7.7.3 Data Collection Period to:

(Year)

Q7.8 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.9 Are data available on the number of people with chronic HBV who were linked to care (assessment of liver function/staging or biomarker testing or treatment) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available

Q7.9.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q7.10 Number of people ever diagnosed with chronic HBV infection (HBsAg) linked to care* during reporting year or year of most recent data:

*defined as receiving specialist or follow-up care.

Q7.10.1 If available: number of people ever diagnosed with chronic HBV infection (HBsAg) linked to care* during reporting year or year of most recent data, within 6 months of diagnosis:

*defined as receiving specialist or follow-up care.

Q7.10.2 Source of data

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q7.10.2.1 Please specify

Q7.10.3 Data Collection Period from:

(Year)

Q7.10.4 Data Collection Period to:

(Year)

Q7.11 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.12 Number people diagnosed with chronic HBV infection (HBsAg) not eligible for treatment** who are retained in care* during reporting year or year of most recent data:

*defined as receiving specialist or follow-up care

**based on clinical guidelines e.g. from the European Association of the Study of the Liver (EASL)

Q7.12.1 Source of data

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q7.12.1.1 Please specify:

Q7.12.2 Data Collection Period from:

(Year)

Q7.12.3 Data Collection Period to:

(Year)

Q7.13 Please provide any further details, including the reference for any available peer reviewed publications:

HBV Continuum of care - General population Treatment

Q7.14 Are data available on number of people diagnosed with chronic HBV receiving treatment in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q7.14.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q7.15 Number of people ever diagnosed with chronic HBV infection (HBsAg), eligible for treatment from a clinical perspective** and receiving antiviral treatment during reporting year or year of most recent data:

**based on clinical guidelines e.g. from the European Association of the Study of the Liver (EASL)

Q7.15.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q7.15.1.1 Please specify

Q7.15.2 Data Collection Period from:

(Year)

Q7.15.3 Data Collection Period to:

(Year)

Q7.16 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.17 Number of people receiving antiviral treatment for chronic HBV infection who have achieved viral suppression during reporting year or year of most recent data:

Q7.17.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q7.17.1.1 Please specify:

Q7.17.2 Data Collection Period from:

(Year)

Q7.17.3 Data Collection Period to:

(Year)

Q7.18 Please provide any further details, including the reference for any available peer reviewed publications:

HCV Continuum of care - General population

Diagnosis

Q7.19 Are data available on the estimated number of people living with chronic HCV (HCV RNA positive) who have been diagnosed in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q7.19.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q7.20 Total number of people ever diagnosed with chronic HCV infection (HCV RNA) up to end of reporting year.

Q7.20.1 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q7.20.1.1 Please specify:

Q7.20.2 Data Collection Period from:

(Year)

Q7.20.3 Data Collection Period to:

(Year)

Q7.20.4 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.21 Total number of people ever diagnosed with chronic HCV infection (HCV RNA) up to end of the reporting year, EXCLUDING those with resolved infection (cured or naturally cleared) and those who have died:

Q7.21.1 Source of data:

- Surveillance
 - Cohort
 - Survey
 - Modelling
 - Other
-

Q7.21.1.1 Please specify:

Q7.21.2 Data Collection Period from:

(Year)

Q7.21.3 Data Collection Period to:

(Year)

Q7.21.4 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.22 Total number of people diagnosed with chronic HCV infection (HCV RNA) during reporting year or year of most recent data:

Q7.22.1 Source of data:

- Surveillance
 - Cohort
 - Survey
 - Modelling
 - Other
-

Q7.22.1.1 Please specify:

Q7.22.2 Data Collection Period from:

(Year)

Q7.22.3 Data Collection Period to:

(Year)

Q7.22.4 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.23 Are data available on proportion of cases of chronic HCV who have decompensated cirrhosis and/or hepatocellular carcinoma upon presentation to care (within 6 months of HCV diagnosis) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q7.23.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q7.24 Percentage of individuals with chronic HCV who have decompensated cirrhosis and/or hepatocellular carcinoma upon presentation to care (within 6 months of HCV diagnosis) (%):

Q7.24.1 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q7.24.1.1 Please specify

Q7.24.2 Data Collection Period from:

(Year)

Q7.24.3 Data Collection Period to:

(Year)

Q7.24.4 Please provide any further details, including the reference for any available peer reviewed publications:

HCV Continuum of care - General population

Linkage to care

Q7.25 Are data available on the number of people with chronic hepatitis C who were linked to care (assessment of liver function/staging or biomarker testing or treatment) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q7.25.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q7.26 Number of people diagnosed with chronic HCV infection (HCV RNA) during reporting year or year of most recent data, who were linked to care*:

*defined as receiving specialist or follow-up care

Q7.26.1 If available: number of people diagnosed with chronic HCV infection (HCV RNA) during reporting year or year of most recent data, who were linked to care* within six months of diagnosis:

Q7.26.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q7.26.2.1 Please specify:

Q7.26.3 Data Collection Period from:

(Year)

Q7.26.4 Data Collection Period to:

(Year)

Q7.27 Please provide any further details, including the reference for any available peer reviewed publications:

HCV Continuum of care - General population Treatment

Q7.28 Are data available on the number of individuals who received antiviral treatment for chronic HCV in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available

Q7.28.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q7.29 Number of people with chronic HCV infection (HCV RNA) who received antiviral treatment during reporting year or year of most recent data:

Q7.29.1 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q7.29.1.1 Please specify:

Q7.29.2 Data Collection Period from:

(Year)

Q7.29.3 Data Collection Period to:

(Year)

Q7.30 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.31 Number of people with chronic HCV infection (HCV RNA) who have EVER received antiviral treatment for chronic HCV, up to end of reporting year:

Q7.31.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q7.31.1.1 Please specify

Q7.31.2 Data Collection Period from:

(Year)

Q7.31.3 Data Collection Period to:

(Year)

Q7.32 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.33 Number of people who received antiviral treatment for HCV with documentation of treatment outcome, during reporting year or year of most recent data:

Q7.33.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q7.33.1.1 Please specify:

Q7.33.2 Data Collection Period from:

(Year)

Q7.33.3 Data Collection Period to:

(Year)

Q7.34 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.35 Number of people who received antiviral treatment for HCV who achieved sustained virological response (SVR) during reporting year or year of most recent data:

Q7.35.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q7.35.1.1 Please specify

Q7.35.2 Data Collection Period from:

(Year)

Q7.35.3 Data Collection Period to:

(Year)

Q7.36 Please provide any further details, including the reference for any available peer reviewed publications:

Q7.37 Are data available on number of people who received antiviral treatment for HCV and achieved SVR and who are enrolled in life-long follow-up, during reporting year or year of most recent data:

- Yes
- No
- Don't know

Q7.37.1 If yes, number of people who received antiviral treatment for HCV, achieved SVR and enrolled in life-long follow-up, during reporting year or year of most recent data:

Q7.37.2 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q7.37.2.1 Please specify

Q7.37.3 Data Collection Period from:

(Year)

Q7.37.4 Data Collection Period to:

(Year)

Q7.38 Please provide any further details, including the reference for any available peer reviewed publications:

8. Continuum of care - People who inject drugs

Please enter the latest available data. If new data are not available, please go to the bottom of the form and tick 'complete' and 'save'.

Continuum of care HCV - People who inject drugs

Q8 Does your country have data on any of the steps along the continuum of care for chronic HCV for people who inject drugs (PWID)?

- Yes, number of people who inject drugs with HCV
 Yes, number of people who inject drugs diagnosed with HCV
 Yes, number of people who inject drugs with HCV linked to care
 Yes, number of people who inject drugs with HCV who achieved SVR
 No data available

Continuum of care - people who inject drugs Estimated number with HCV

Q8.0 Are data available on the estimated number of all people who inject drugs with current chronic hepatitis C (HCV RNA positive, diagnosed and undiagnosed) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available

Q8.0.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q8.1 Estimated number of all people who inject drugs with current chronic hepatitis C (HCV RNA positive) (diagnosed and undiagnosed), up to end of reporting year:

Q8.1.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q8.1.1.1 Please specify

Q8.1.2 Data Collection Period from:

(Year)

Q8.1.3 Data Collection Period to:

(Year)

Q8.2 Please provide any further details, including the reference for any available peer reviewed publications:

Continuum of care - people who inject drugs

Diagnosis

Q8.3 Are data available on the estimated number of people who inject drugs living with chronic HCV (HCV RNA positive), who have been diagnosed in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please indicate the largest geographical level for which data are available.

Q8.3.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q8.4 Total number of people who inject drugs ever diagnosed with chronic HCV infection (HCV RNA) up to the end of the reporting year:

Q8.4.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q8.4.1.1 Please specify

Q8.4.2 Data Collection Period from:

(Year)

Q8.4.3 Data Collection Period to:

(Year)

Q8.4.4 Please provide any further details, including the reference for any available peer reviewed publications:

Q8.5 Total number of people who inject drugs ever diagnosed with chronic HCV infection (HCV RNA) up to the end of reporting year, EXCLUDING those with resolved infection (cured or naturally cleared) and those who have died:

Q8.5.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q8.5.1.1 Please specify

Q8.5.2 Data Collection Period from:

(Year)

Q8.5.3 Data Collection Period to:

(Year)

Q8.5.4 Please provide any further details, including the reference for any available peer reviewed publications:

Q8.6 Total number of people who inject drugs diagnosed with chronic HCV infection (HCV RNA) during reporting year or year of most recent data:

Q8.6.1 Source of data

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q8.6.1.1 Please specify

Q8.6.2 Data Collection Period from:

(Year)

Q8.6.3 Data Collection Period to:

(Year)

Q8.6.4 Please provide any further details, including the reference for any available peer reviewed publications:

HCV Continuum of care - People who inject drugs

Linkage to Care

Q8.7 Are data available on the number of people who inject drugs with chronic HCV, who were linked to care (assessment of liver function/staging or biomarker testing or treatment) in your country?

- National-level data available
- Regional-level data available
- City-level data available
- Clinic-level data available
- No data available

Please indicate the largest geographical level for which data are available.

Q8.7.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q8.8 Number of people who inject drugs diagnosed with chronic HCV infection (HCV RNA) during reporting year or year of most recent data, who were linked to care*:

*defined as receiving specialist or follow-up care

Q8.8.1 If available: number of people who inject drugs diagnosed with chronic HCV infection (HCV RNA) during reporting year or year of most recent data, who were linked to care* within six months of diagnosis:

*defined as receiving specialist or follow-up care

Q8.8.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q8.8.2.1 Please specify:

Q8.8.3 Data Collection Period from:

(Year)

Q8.8.4 Data Collection Period to:

(Year)

Q8.8.5 Please provide any further details, including the reference for any available peer reviewed publications:

HCV Continuum of care - people who inject drugs Treatment and Sustained Virological Response

Q8.9 Are data available on the number of people who inject drugs who received antiviral treatment for chronic HCV in your country?

Please indicate the largest geographical level for which data are available.

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Q8.9.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q8.10 Number of people who inject drugs with chronic HCV infection (HCV RNA), who received antiviral treatment, during reporting year or year of most recent data:

Q8.10.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q8.10.1.1 Please specify:

Q8.10.2 Data Collection Period from:

(Year)

Q8.10.3 Data Collection Period to:

(Year)

Q8.11 Please provide any further details, including the reference for any available peer reviewed publications:

Q8.12 Number of people who inject drugs with chronic HCV infection (HCV RNA), who have EVER been treated up to end of reporting year:

Q8.12.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q8.12.1.1 Please specify

Q8.12.2 Data Collection Period from:

(Year)

Q8.12.3 Data Collection Period to:

(Year)

Q8.13 Please provide any further details, including the reference for any available peer reviewed publications:

Q8.14 Number of people who inject drugs who received antiviral treatment for HCV, with documentation of treatment outcome, during reporting year or year of most recent data with documentation of treatment outcome:

Q8.14.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q8.14.1.1 Please specify

Q8.14.2 Data Collection Period from:

(Year)

Q8.14.3 Data Collection Period to:

(Year)

Q8.15 Please provide any further details, including the reference for any available peer reviewed publications:

Q8.16 Number of people who inject drugs who received antiviral treatment for HCV and who achieved sustained virological response during reporting year or year of most recent data:

Q8.16.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q8.16.1.1 Please specify:

Q8.16.2 Data Collection Period from:

(Year)

Q8.16.3 Data Collection Period to:

(Year)

Q8.17 Please provide any further details, including the reference for any available peer reviewed publications:

9. Continuum of care - People in prison

Please enter the latest available data. If new data are not available, please go to the bottom of the form and tick 'complete' and 'save'.

Continuum of care HCV - People in prisons

Q9 Does your country have data on any of the steps along the continuum of care for chronic HCV for people in prison?

- Yes, number of people in prison with HCV
 Yes, number of people in prison diagnosed with HCV
 Yes, number of people in prison with HCV linked to care
 Yes, number of people in prison with HCV who achieved SVR
 No data available

Continuum of care - people in prison Estimated number with HCV

Q9.0 Are data available on the estimated number of all people in prison with current chronic hepatitis C (RNA positive, diagnosed and undiagnosed) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please provide data from the largest geographical level for which data are available

Q9.0.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q9.1 Estimated number of all people in prison with current chronic hepatitis C (HCV RNA positive), diagnosed and undiagnosed, during reporting year or year of most recent data:

Q9.1.1 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q9.1.1.1 Please specify:

Q9.1.2 Data Collection Period from:

(Year)

Q9.1.3 Data Collection Period to:

(Year)

Q9.2 Please provide any further details, including the reference for any available peer reviewed publications:

Q9.3 Are data available on the estimated proportion of people in prison with current chronic HCV (RNA positive, diagnosed and undiagnosed) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please provide data from the largest geographical level for which data are available

Q9.3.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q9.4 Estimated proportion of people in prison with current chronic HCV (HCV RNA positive), (diagnosed and undiagnosed), during reporting year of year of most recent data:

Q9.4.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q9,4,1,1 Please specify

Q9.4.2 Data Collection Period from:

(Year)

Q9.4.3 Data Collection Period to:

(Year)

Q9.5 Please provide any further details, including the reference for any available peer reviewed publications:

Continuum of care - people in prison

Diagnosis

Q9.6 Are data available on the estimated number of people in prisons living with chronic HCV (HCV RNA positive) who have been diagnosed in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please provide data from the largest geographical level for which data are available

Q9.6.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q9.7 Total number of people in prisons ever diagnosed with chronic HCV infection (HCV RNA) up to the end of reporting year:

Q9.7.1 Source of data

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q9.7.1.1 Please specify

Q9.7.2 Data Collection Period from:

(Year)

Q9.7.3 Data Collection Period to:

(Year)

Q9.7.4 Please provide any further details, including the reference for any available peer reviewed publications:

Q9.8 Total number of people in prisons ever diagnosed with chronic HCV infection (HCV RNA) up to the end of reporting year, EXCLUDING those with resolved infection (cured or naturally cleared) and those who have died:

Q9.8.1 Source of data

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q9.8.1.1 Please specify

Q9.8.2 Data Collection Period from:

(Year)

Q9.8.3 Data Collection Period to:

(Year)

Q9.8.4 Please provide any further details, including the reference for any available peer reviewed publications:

Q9.9 Total number of people in prisons diagnosed with chronic HCV infection (HCV RNA) during reporting year or year of most recent data:

Q9.9.1 Source of data

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q9.9.1.1 Please specify

Q9.9.2 Data Collection Period from:

(Year)

Q9.9.3 Data Collection Period to:

(Year)

Q9.9.4 Please provide any further details, including the reference for any available peer reviewed publications:

HCV Continuum of care - People who inject drugs Linkage to Care

Q9.10 Are data available on the number of people in prisons with chronic HCV who were linked to care (assessment of liver function/staging or biomarker testing or treatment) in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please provide data from the largest geographical level for which data are available.

Q9.10.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q9.11 Number of people in prisons diagnosed with chronic HCV infection (HCV RNA) during reporting year or year of most recent data, who were linked to care*:

*defined as receiving specialist or follow-up care

Q9.11.1 If available: number of people in prisons diagnosed with chronic HCV infection (HCV RNA) during reporting year or year of most recent data, who were linked to care* within six months of diagnosis:

Q9.11.2 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q9.11.2.1 Please specify:

Q9.11.3 Data Collection Period from:

(Year)

Q9.11.4 Data Collection Period to:

(Year)

Q9.11.5 Please provide any further details, including the reference for any available peer reviewed publications:

HCV Continuum of care - people who inject drugs Treatment and Sustained Virological Response

Q9.12 Are data available on the number of people in prisons who received antiviral treatment for chronic HCV in your country?

- National-level data available
 Regional-level data available
 City-level data available
 Clinic-level data available
 No data available

Please provide data from the largest geographical level for which data are available.

Q9.12.1 Please specify the regions(s), city(ies), or clinic(s) from which data are available:

Q9.13 Number of people in prisons with chronic HCV infection (HCV RNA) who received antiviral treatment during reporting year or year of most recent data:

Q9.13.1 Source of data:

- Surveillance
 Cohort
 Survey
 Modelling
 Other

Q9.13.1.1 Please specify:

Q9.13.2 Data Collection Period from:

(Year)

Q9.13.3 Data Collection Period to:

(Year)

Q9.14 Please provide any further details, including the reference for any available peer reviewed publications:

Q9.15 Number of people in prisons with chronic HCV infection (HCV RNA) who have EVER been treated up to end of reporting year:

Q9.15.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q9,15.1.1 Please specify:

Q9.15.2 Data Collection Period from:

(Year)

Q9.15.3 Data Collection Period to:

(Year)

Q9.16 Please provide any further details, including the reference for any available peer reviewed publications:

Q9.17 Number of people in prisons who received antiviral treatment for HCV with documentation of treatment outcome, during reporting year or year of most recent data with documentation of treatment outcome:

Q9.17.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q9,17.1.1 Please specify:

Q9.17.2 Data Collection Period from:

(Year)

Q9.17.3 Data Collection Period to:

(Year)

Q9.18 Please provide any further details, including the reference for any available peer reviewed publications:

Q9.19 Number of people in prisons who received antiviral treatment for HCV who achieved sustained virological response/functional cure during reporting year or year of most recent data:

Q9.19.1 Source of data:

- Surveillance
- Cohort
- Survey
- Modelling
- Other

Q9.19.1.1 Please specify:

Q9.19.2 Data Collection Period from:

(Year)

Q9.19.3 Data Collection Period to:

(Year)

Q9.20 Please provide any further details, including the reference for any available peer reviewed publications:
